Yale Canine Cancer Vaccine
Saturday, Oct 3, 2020
1:00pm – 2:30pm EST (Zoom)
Professor Mark Mamula
Yale University School of Medicine
Canine osteosarcoma is the most common primary skeletal tumor in dogs. Despite relatively aggressive standard-of-care treatment consisting of amputation and adjuvant chemotherapy, survival times are limited to a median of 9-11 months.
In this talk, Dr. Mark Mamula will describe a new Epidermal Growth Factor Receptor (EGFR) peptide-based cancer vaccine. He will review his preliminary findings, including safety and efficacy data from a clinical study involving canine patients with osteosarcoma, hemangiosarcoma, and other malignancies linked to EGFR over-expression.
The seminar is followed by a Q&A session.
Mark Mamula, PhD
Professor of Medicine (Rheumatology)
Dr. Mamula’s received degrees from UCLA, the University of Notre Dame, and the University of Oklahoma. Dr. Mamula’s central research interests are in investigating the early events involved with breaking immune tolerance to self-proteins, both in autoimmune disease and in tumor biology. Overall, it is the goal of Dr. Mamula's laboratory to understand the mechanisms that may shift this balance toward the initiation of anti-self immune responses. Seminal work from the Mamula lab elucidated the biochemical forms of autoantigens capable of breaking immunologic tolerance to intracellular autoantigens in systemic lupus erythematosus (SLE), and type 1 diabetes (T1D). These studies have now been applied to the development of novel therapeutic approaches in developing anti-tumor vaccines in breast cancer and colon cancer. In addition, studies from the Mamula laboratory first demonstrated the ability of B cells to present autoantigens in the triggering of T cell autoimmunity and in the phenomenon of epitope spreading in lupus autoimmunity. This work preceded more recent studies illustrating how the B cells transfer autoantigens to other antigen-presenting cells, including dendritic cells and macrophages. Dr. Mamula is currently studying the impact of EGFR peptide-based vaccine on extending survival times for canine cancer patients.
The Yale Canine Cancer Vaccine Seminar is an event hosted by
Canine Cancer Research Alliance, a 501(c)(3) foundation.